aTyr Pharma, Inc.
ATYR
$3.99
$0.4412.39%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -- |
| Cost of Revenue | 43.49% | 42.00% | 42.49% | -14.45% | 4.58% |
| Gross Profit | -48.58% | -42.00% | -39.98% | -181.94% | -1.00% |
| SG&A Expenses | 25.93% | -10.11% | 2.90% | -6.48% | -26.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.91% | 27.71% | 31.94% | -12.96% | -3.88% |
| Operating Income | -43.82% | -27.71% | -30.10% | -100.74% | 6.50% |
| Income Before Tax | -52.19% | -32.12% | -29.58% | -96.21% | 14.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.19% | -32.12% | -29.58% | -96.21% | 14.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00% | -- | -500.00% | -50.00% | 100.00% |
| Net Income | -52.20% | -32.16% | -29.62% | -96.25% | 14.38% |
| EBIT | -43.82% | -27.71% | -30.10% | -100.74% | 6.50% |
| EBITDA | -44.42% | -27.92% | -29.52% | -99.52% | 7.47% |
| EPS Basic | -16.23% | -0.85% | 17.81% | 3.56% | 57.61% |
| Normalized Basic EPS | -16.26% | -0.86% | 17.84% | 3.53% | 57.62% |
| EPS Diluted | -16.23% | -0.85% | 17.81% | 5.25% | 57.61% |
| Normalized Diluted EPS | -16.26% | -0.86% | 17.84% | 3.53% | 57.62% |
| Average Basic Shares Outstanding | 30.95% | 31.08% | 57.72% | 103.53% | 101.95% |
| Average Diluted Shares Outstanding | 30.95% | 31.08% | 57.72% | 103.53% | 101.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
